Therapeutic efficacy and safety of Unani formulation in patients of Fasaad-e-tashahhum-e-dam (dyslipidemia): a randomized open standard controlled clinical study

Syed Sabahat, Naquib Ul-Islam


Background: Hyperlipidemia which is interchangeably used with the term dyslipidemia essentially refers to the condition of abnormality of lipid levels measured in the blood typically due to the disorder of lipoprotein metabolism. The objective of this study was to determine the therapeutic effect and safety of newly formulated drug on patients with Fasaad-e-Tashahhum-e-Dam (dyslipidemia) and compare it with the effect of Unani formulation and rosavastatin.

Methods: The present study was open randomized controlled clinical study. The study subjects were divided in two groups, one group was given test drug (test group) and another group was given control drug (control group). All the patients who qualified the inclusion criteria were randomly placed in either test or control group.

Results: In the present study we observed that both the groups were comparable with respect to age, sex lifestyle, family history and mizaj. We found that both Unani formulated drug and standard drug rosavastatin significantly improves the lipid parameters after the treatment with a p value of (<0.001*).

Conclusions: We concluded that the overall effect of the proposed Unani formulated drug was found quite fascinating in the treatment of dyslipidemia. Apart from drug safety, visible improvements were evident in objective parameters like cholesterol, triglyceride and LDL, VLD. However, the present study did not revealed that Unani drug is superior to standard drug instead both the treatments are equally effective on the improvement of lipid profile parameters.


Fasaad-e-tashahhum-e-dam, Lipid, Unani, Rosavastatin

Full Text:



Mahmood ZA, Ahmad SW, Sualeh M, Mehmood SBZ. Hyperlipidemia Development and Consequences. Medical Channel. 2009;15(3):14-5.

Basak CR, Chatterjee M, Sarma PAS. An overview on management of diabetic dyslipidemia. J diabetes endocrinol. 2013;4(3):27-36.

Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 1997;349(9061):1269-76.

Hub Pages. Dyslipidemia - Symptoms, Causes, Diagnosis and Treatment, 2013. Available at: Accessed on 18 June 2021.

Paccaud F, Schluter FV, Wietlisbach V, Bovet P. Dyslipidemia and abdominal obesity: an assessment in three general populations. J Clin Epidemiol. 2000;53(4):393-400.

Shah SN. API text book of medicine, Volume II. 8th ed. Mumbai: The Association of India; 2008: 954- 955.

Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, Loscalzo J. Harrison’s Principles of Internal Medicine. 19th ed. New York, NY: McGraw Hill; 2015: 2438-2449.

Laurence B, Chabner B, Knollman B. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. USA: McGraw Hill; 2001: 984-995.

Sawami AM, ShettyDhanashri, Mankeshwar R, Ashvaid Tester F. Prevalence of dyslipidemia in young adult Indian population. JAPI. 2008;56:99-102.

Longe J, Deirdres B. The Gale encyclopaedia of medicine, Volume 2. 2nd ed. USA: Farmington Hills; 2002: 1709.

Rabia A, Zaini AM, Aidiahmad D, Ihtisham UM. Sources and possible mechanisms of action of important phyto-constituents with cardiovascular properties. African J Pharma Pharmacol. 2012;6(9): 563-80.

Basak A. Inhibitors of proprotein convertases. J Mol Med. 2005;83:844-55.

Goldman L, Dennis A. Cecil Textbook of medicine, Volume 22. 22nd ed. New Delhi: Elsivier Inc; 2004: 1258-1267.

Lango DL. Harrison’s Principal of Internal Medicine, Volume 2. 18th ed. USA: McGraw Hill; 2012: 3146-3156.

CCRUM. Hippocratic Journal of Unani Medicine, Volume 11. New Delhi: CCRUM; 1986: 45-308.

Hakim MA. Bustan-ul-Mufradat. Islam: Islamic Health and Medicine; 2002: 52-573.

Khan H. Majmaul Bahrain. Lucknow: Mataba Munshi Naval Kishore; 1903: 1294.